期刊文献+

基于甲氧基聚乙二醇-胆固醇的新型胶束载体研究 被引量:1

Novel Micellar Delivery System Based on Methoxy Poly(ethylene glycol)-Cholesterol
原文传递
导出
摘要 目的合成新型载体材料甲氧基聚乙二醇-胆固醇,并对其胶束成型工艺和毒性进行系统研究,为其作为药物载体提供参考。方法丁二酰化胆固醇与聚乙二醇单甲醚通过酯键偶联,合成甲氧基聚乙二醇-胆固醇;通过共溶剂蒸发法、乳化溶剂蒸发法和薄膜分散法将甲氧基聚乙二醇-胆固醇制备成胶束;并采用MCF-7、MDA-MB-231、4T1、SKOV-3和AD293细胞对胶束的毒性进行系统评价。结果两步反应即可制得甲氧基聚乙二醇-胆固醇,产率高达70.3%。3种方法均可成功制得甲氧基聚乙二醇-胆固醇胶束,粒径为20~150 nm。甲氧基聚乙二醇-胆固醇材料本身与其胶束浓度低于20μmol·L-1没有显著毒性;制备成胶束后对SKOV-3及MCF-7的IC50值明显降低。结论甲氧基聚乙二醇-胆固醇合成工艺简单、成本低廉、易于放大生产,胶束成型工艺简单,毒性较低,可用于包载溶解特性不同的药物,是一种有广泛应用前景的胶束载体。 ObjectiveTo synthesize methoxy poly(ethylene glycol)-cholesterol(mPEG-Chol), prepare mPEG-Chol micelles and investigate the in vitro cytotoxicity. Methods mPEG-Chol was achieved by conjugating cholesterol succinic ester(Chol-suc) with mPEG. mPEG-Chol micelles were constructed through different Methods including co-evaporation method, emulsion evaporation method and film dispersion method. The cytotoxicity of micelles was assessed systemically on different cell lines including MCF-7, MDA-MB-231, 4T1, SKOV-3 and AD293. Results mPEG-Chol was synthesized successfully with the yield of 70.3% and could form micelles via three different Methods. The size of mPEG-Chol micelles ranged from 20 to 150 nm. mPEG-Chol had no cell growth inhibition activity when set at the concentration of 20 μmol·L-1. The micelles showed different cytotoxicity compared with the mPEG-Chol molecular form. The IC50 values of micelles to SKOV-3 and MCF-7 were significantly lower than molecules. Conclusion The synthesis process of mPEG-Chol is simple, cost-effective and easy to scale up massively. Micelles with low toxicity could be fabricated easily. Therefore, mPEG-Chol would be one of potential biomaterials to encapsulate various drugs with different solubility.
出处 《中国药学杂志》 CAS CSCD 北大核心 2013年第14期1178-1182,共5页 Chinese Pharmaceutical Journal
基金 国家自然科学基金资助项目(30901868)
关键词 甲氧基聚乙二醇-胆固醇 胶束 毒性 制备方法 MPEG-Chol, micelle, toxicity, preparation
  • 相关文献

参考文献3

二级参考文献77

  • 1王佳蕾,洪小南,印季良,杜敏琼,周彩存,熊建萍,徐农,陈颖波,许立功,侯惠民.紫杉醇脂质体与紫杉醇治疗非小细胞肺癌64例和乳腺癌62例的疗效[J].中国新药与临床杂志,2006,25(1):1-4. 被引量:19
  • 2张永,涂家生,沈雁,杨小燕.注射用紫杉醇聚合物胶束小鼠体内药代动力学[J].中国药科大学学报,2007,38(4):343-346. 被引量:10
  • 3di PAOLO D, PASTORINO F, BRIGNOLE C, et al. Drug delivery systems: application of liposomal anti-tumor agents to neuroectodermal cancer treatment[J]. Tumori, 2008, 94(2): 246-253.
  • 4TOMA S, TUCCI A, VILLANI G, et al. Liposomal doxorubiein (Caelyx) in advanced prelreated soft tissue sarcomas: a phase Ⅱ study of the Italian Sarcoma Group (ISG)[J]. Anticancer Res, 2000, 20(1B) : 485-491.
  • 5SWENSON CE, BOLCSAK LE, BATIST G, et al. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D- 99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastalic breast cancer [J]. Anticancer Drugs, 2003, 14(3): 239-246.
  • 6FORSSEN EA. The design and development of DaunoXome for solid tumor targeting in vivo[J]. Adv Drug Deliv Rev, 1997, 24(2-3): 133-150.
  • 7GILL PS, ESPINA BM, MUGGIA F, et al. Phase Ⅰ/Ⅱ clinical and pharmacokinetic evaluation of liposomal daunorubicin [J]. J Clin Oncol, 1995, 13: 996.
  • 8MANTRIPRAGADA S. A lipid based depot (DepoFoam technology) for sustained release drug delivery [J]. Prog Lipid Res, 2002, 41(5) : 392-406.
  • 9CULLIS PR, CHONN A. Recent advances in liposome technologies and their applications for systemic gene delivery [J]. Adv Drug Deliv Rev, 1998, 30(1-3) : 73-83.
  • 10GOEBEL FD, GOLDSTEIN D, GOO S M, et al. Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's The International SL-DOX Study Group [J]. Brit J Cancer, 1996, 73(8): 989-994.

共引文献14

同被引文献17

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部